Immunovant Inc. (NASDAQ:IMVT) Director Atul Pande sold 1,500 shares of the company's common stock on July 24, 2026, resulting in a total transaction value of $59,699. The sale was disclosed in a recent filing with the Securities and Exchange Commission. Each share was disposed of at a price of $39.80. This transaction was carried out under the framework of a Rule 10b5-1 Plan, which Pande established on December 26, 2025. The execution price sits close to the company's 52-week high of $41.23, underscoring Immunovant's robust annual performance with shares having surged 133% over the past year. Valuation analysis from InvestingPro suggests the stock may be overvalued relative to its fair value, positioning it among the most overvalued equities in the market.
Before executing the sale, Mr. Pande acquired the identical 1,500 shares through the exercise of stock options. These options were purchased at an exercise price of $8.43 per share, totaling $12,645. The options were part of a fully vested award of stock options to purchase common shares. Following these transactions, Atul Pande directly beneficially owns 116,731 shares of Immunovant common stock. Additionally, 20,000 shares are indirectly beneficially owned by a Trust. Mr. Pande also holds 66,681 derivative securities in the form of stock options.
Recent analyst activity surrounding Immunovant has been notably positive. H.C. Wainwright raised its price target for Immunovant shares to $40, maintaining a Buy rating. This update was based on promising response rates from the company's Phase 2 rheumatoid arthritis study. The study reported significant response rates, with 72.7% achieving ACR20, 54.5% ACR50, and 35.8% ACR70 at week 16 among 165 highly refractory patients. Similarly, BofA Securities increased its price target to $43, also maintaining a Buy rating. The firm cited an improved peak sales outlook for IMVT-1402, now projected at $6.8 billion. This outlook is driven by potential contributions from treatments for Graves' disease and challenging cases of rheumatoid arthritis. Stifel reaffirmed its Buy rating and $49 price target, emphasizing the trial's high response rates and the complexity of cross-trial comparisons due to patient enrichment strategies.
Roivant Sciences, which includes Immunovant in its portfolio, reported its fourth-quarter earnings for fiscal year 2026. While Roivant missed its earnings per share expectations, the company highlighted a strong cash position and strategic growth in its product pipeline. Immunovant Inc. is included in AI-picked strategies. The stock closed at $39.41, up $0.04 or 0.10%. After-hours trading showed no change at $39.41. Investors can review strategies and analyze IMVT through available platforms. The article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Is your IMVT trade worth the risk? Before you click buy, know exactly where to set your stop-loss. Our Vision AI literally sees your IMVT chart and delivers a complete risk management plan, entry, stop-loss, and profit target, in under 60 seconds. Protect your downside. Validate every trade. Invest smarter. July Sale - 60% Off InvestingPro.